Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Magnetic Resonance Imaging Response of the Dominant Intraprostatic Lesion After Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer and Correlation With Prostate Specific Antigen Response (PRODART)

NCT06822491 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT06822491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06822491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Magnetic Resonance Imaging Response of the Dominant Intraprostatic Lesion After Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer and Correlation With Prostate Specific Antigen Response (PRODART)
Lead sponsor
University of Zurich
Phase
Observational
Overall status
Active, not recruiting
Start date
August 20, 2024
Completion date
June 30, 2031
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

localized prostate adenocarcinoma, magnetic resonance imaging, multiparametric mri, prostate carcinoma, stereotactic body radiotherapy, stereotactic radiotherapy